Clinical Research Disease Treatment White Paper 
Conversations in Drug Development Trends
MARCH 20, 2024
One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial. As the study of how an individual’s genes affect their response to drugs, pharmacogenomics is a critical factor in developing effective and safe drugs and dosages in clinical trials.
PPD
OCTOBER 12, 2023
These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. DOWNLOAD OUR WHITE PAPER Learn more about how PPD® Laboratory services can enhance your CGT projects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PPD
MARCH 21, 2024
Food and Drug Administration defines these groups as: Neonates: newborns up to 1 month Infants: 1 month–2 years Children: 2–12 years Adolescents: 12–16 years Pediatric clinical trials must account for different age groups and developmental stages, as children’s physiology and response to treatments can vary significantly.
The Pharma Data
SEPTEMBER 11, 2020
While stories from news outlets indicate the peak of the infection has passed in most European countries, cases of the disease continue to rise in other parts of the world, especially Latin America and Africa. Covid-19 command center aims to accelerate clinical research by individual sponsors to combat disease.
Conversations in Drug Development Trends
MARCH 12, 2024
From their use in risk and safety assessments to patient screening and treatment efficacy, biomarkers offer minimally invasive, objective data. For a more in-depth look at biomarkers, check out our white paper. Deviations from established baseline values provide insights into treatment response in certain cancer indications.
Conversations in Drug Development Trends
MARCH 1, 2024
Master protocols allow a trial to perform multiple tests on diverse patient populations or diseases under a unified design. Umbrella Studies Umbrella studies evaluate multiple investigational products (IPs) within a single disease. But how do they work, and when are they appropriate? What Are Master Protocols? Contact us.
Agency IQ
FEBRUARY 21, 2024
Given the widespread use of CDISC for clinical research and HL7 for electronic health record (EHR) data, the two organizations have partnered to create mapping guides to streamline the flow of data from EHRs to CDISC submission-ready datasets, and vice versa. CMS in the United States ).
Expert insights. Personalized for you.
52 
Let's personalize your content